References
- Deschuyteneer M, et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin 2010;6:407-19
- Mach H, et al. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 2006;95:2195-206
- Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009;200:166-71
- F.D.A. Package insert - Gardasil. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm Accessed 31-1-2011
- F.D.A. Package insert -- Cervarix. Available from: http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm186957.htm Accessed 31-1-2011
- SPC Cervarix. Available from: http://www.medicines.org.uk/emc/medicine/20204/SPC/Cervarix/ Accessed 31-1-2011
- SPC Gardasil. Available from: http://www.medicines.org.uk/EMC/medicine/19016/SPC/GARDASIL/ Accessed 31-1-2011
- Dessy F, et al. Comparative evaluation of the immunogenicity of two prophylactic HPV cervical cancer vaccines by Merck's competitive Luminex immunoassay (CLIA) and GSK's binding ELISA (Abstract n° P IM-5 presented at the EUROGIN 2010 Congress, Monte-Carlo, Monaco, 17–20 Feb). 216. 2010. Paris, Eurogin. Abstracts
- Einstein MH, et al. Comparison of the immunogenicity and safety of Cervarix(TM) and Gardasil(R) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18--45 years. Hum Vaccin 2009;5:702-16
- Rowhani-Rahbar A, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009;27:5612-19
- Paavonen J, et al. End-of-study results of PATRICIA: a phase III efficacy study of HPV-16/18 AS04-adjuvanted vaccine in young women. (Abstract n° P-689 presented at the 26th International Papillomavirus Conference & Clinical and Public Health Workshops, Montréal, Canada, 3–8 July), 2010
- Brisson M, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25:5399-408
- Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359:821-32
- Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010;28:5473-84
- Brown DR, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999;37:3316-22
- Aubin F, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008;47:610-15
- Vandepapeliere P, et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005;192:2099-107
- Lefebvre CD, et al. An appraisal of the burden of genital warts, from a healthcare and individual patient perspective. Public Health 2011; Accepted for publication
- Standaert B, et al. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine 2010;28(Suppl 6):G30-8
- Bamfi F, et al. Epidemiologia e costi dei condilomi ano-genitali in Italia: revisione delle evidenze disponibili. Farmeconomia e percorsi terapeutici 2008;9:183-9
- Vittori G, et al. A new approach to estimate genital warts incidence and prevalence in the Italian general population. It J Gynaecol Obstet 2008;20:33-42